Casgevy, Lyfgenia Medicare Add-On Payments In Sickle Cell Are Not Conditioned On Outcomes-Based Contracting

 
• By Cathy Kelly
  
Generate a summary of this article
Listen to this article
Beta

The CMS supplemental reimbursement for the gene therapies is higher than usual for new technologies, but is similar to the formula used for antibiotics.

Hospitals Still Face High Medical Costs Associated With the Gene Therapies Treatment. • Source: Shutterstock

Multi-million dollar gene therapies for sickle cell disease from Vertex Pharmaceuticals Incorporated and bluebird bio will get a Medicare reimbursement boost in 2025 and up to two years afterward, which could help encourage uptake by healthcare providers.

Key Takeaways

  • Vertex’s Casgevy and bluebird bio’s Lyfgenia were awarded Medicare new technology add-on payments for use in sickle cell disease starting in 2025.

The Centers for Medicare and Medicaid Services announced 1 August that Medicare will pay the lesser of:

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Cell & Gene Therapies

test carousel-PINKSHEET

 
• By Saba Afreen

test carousel-test

Diversity Action Plans Should Be Brief And Waiver Requests Filed Early, US FDA Says - Clone

 
• By Sue Sutter

In what could amount to a de facto enforcement mechanism, the new draft guidance also “strongly encourages” sponsors to share details about their diversity action plan and enrollment goals with the public.

Testing all options - Akash

 
• By Akash

This is an test article.

More from Advanced Technologies

CAR-T Therapies: Rethinking Of Postmarketing Requirements And REMS Urged

 
• By Sue Sutter

Long-term follow-up requirements have taken a conservative approach but could be ripe for re-examination and global harmonization given the years of experience with the products, Kite Pharma executive director says; former FDA gene/cell therapy office head Wilson Bryan calls for elimination of the classwide REMS.

test

 
• By Sabbah and Saba Afreen

test

Gene Therapies: CoGenT Pilot Could Help With Regulatory Convergence Earlier In Development TEST

 
• By Sue Sutter

Program for collaborative reviews of gene therapy applications is getting under way with the European Medicines Agency. After launch, the pilot could be expanded to earlier discussions around CMC and pharm/tox data requirements, FDA’s Nicole Verdun said.